These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28847911)

  • 1. Novel Index of Maladaptive Myocardial Remodeling in Hypertension.
    Goh VJ; Le TT; Bryant J; Wong JI; Su B; Lee CH; Pua CJ; Sim CPY; Ang B; Aw TC; Cook SA; Chin CWL
    Circ Cardiovasc Imaging; 2017 Sep; 10(9):e006840. PubMed ID: 28847911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction.
    Hieda M; Sarma S; Hearon CM; Dias KA; Martinez J; Samels M; Everding B; Palmer D; Livingston S; Morris M; Howden E; Levine BD
    Circulation; 2020 Jan; 141(2):115-123. PubMed ID: 31865771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
    Treibel TA; Zemrak F; Sado DM; Banypersad SM; White SK; Maestrini V; Barison A; Patel V; Herrey AS; Davies C; Caulfield MJ; Petersen SE; Moon JC
    J Cardiovasc Magn Reson; 2015 Aug; 17(1):74. PubMed ID: 26264919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis).
    Peters MN; Seliger SL; Christenson RH; Hong-Zohlman SN; Daniels LB; Lima JAC; de Lemos JA; Neeland IJ; deFilippi CR
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).
    Seliger SL; de Lemos J; Neeland IJ; Christenson R; Gottdiener J; Drazner MH; Berry J; Sorkin J; deFilippi C
    JACC Heart Fail; 2015 Jun; 3(6):445-455. PubMed ID: 25982111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.
    Neeland IJ; Drazner MH; Berry JD; Ayers CR; deFilippi C; Seliger SL; Nambi V; McGuire DK; Omland T; de Lemos JA
    J Am Coll Cardiol; 2013 Jan; 61(2):187-95. PubMed ID: 23219305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes.
    Rodrigues JC; Amadu AM; Dastidar AG; Szantho GV; Lyen SM; Godsave C; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Nightingale AK; Paton JF; Manghat NE; Bucciarelli-Ducci C
    Heart; 2016 Oct; 102(20):1671-9. PubMed ID: 27260191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.
    Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
    J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects.
    Ojji DB; Opie LH; Lecour S; Lacerda L; Adeyemi OM; Sliwa K
    Cardiovasc J Afr; 2014; 25(5):233-8. PubMed ID: 25629540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy.
    Le TT; Lim V; Ibrahim R; Teo MT; Bryant J; Ang B; Su B; Aw TC; Lee CH; Bax J; Cook S; Chin CWL
    Eur Heart J Cardiovasc Imaging; 2021 May; 22(6):670-679. PubMed ID: 32255186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-contrast cardiac CT immediately after percutaneous coronary intervention: does it predict the risk of left ventricular remodeling in patients with ST-elevation myocardial infarction?
    Khurelsukh K; Kim YH; Seon HJ; Song JH; Park SY; Moon SM; Kim SH; Sim DS; Ahn Y
    Int J Cardiovasc Imaging; 2016 Jun; 32 Suppl 1():147-54. PubMed ID: 27139462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological, electrical and echocardiographic indices versus cardiac magnetic resonance imaging in diagnosing left ventricular hypertrophy.
    Courand PY; Gaudebout N; Mouly-Bertin C; Thomson V; Fauvel JP; Bricca G; Lantelme P
    Hypertens Res; 2014 May; 37(5):444-51. PubMed ID: 24132010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-flow severe aortic stenosis with preserved ejection fraction, N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiovascular remodeling.
    Mizia-Stec K; Adamczyk T; Mizia M; Haberka M; Gasior Z; Trusz-Gluza M; Tendera M
    J Heart Valve Dis; 2011 May; 20(3):301-10. PubMed ID: 21714421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echocardiographic assessment and N-terminal pro-brain natriuretic peptide in hypertensives with metabolic syndrome.
    Krzesiński P; Uziebło-Życzkowska B; Gielerak G; Stańczyk A; Piotrowicz K; Piechota W; Smurzyński P; Skrobowski A
    Adv Clin Exp Med; 2017; 26(2):295-301. PubMed ID: 28791849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients.
    Rao NN; Stokes MB; Rajwani A; Ullah S; Williams K; King D; Macaulay E; Russell CH; Olakkengil S; Carroll RP; Faull RJ; Teo KSL; McDonald SP; Worthley MI; Coates PT
    Circulation; 2019 Jun; 139(25):2809-2818. PubMed ID: 31045455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension.
    Partanen N; Husso M; Vuolteenaho O; Sipola P; Ruskoaho H; Peuhkurinen K; Magga J
    J Hum Hypertens; 2011 Dec; 25(12):746-51. PubMed ID: 21248782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension.
    Verdecchia P; Angeli F; Mazzotta G; Bartolini C; Garofoli M; Aita A; Poltronieri C; Pinzagli MG; Valecchi F; Martone S; Ramundo E; Turturiello D; Reboldi G
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28539381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
    Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Dimorphism in the Myocardial Response to Aortic Stenosis.
    Treibel TA; Kozor R; Fontana M; Torlasco C; Reant P; Badiani S; Espinoza M; Yap J; Diez J; Hughes AD; Lloyd G; Moon JC
    JACC Cardiovasc Imaging; 2018 Jul; 11(7):962-973. PubMed ID: 29153564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study.
    Martinez-Rumayor AA; de Lemos JA; Rohatgi AK; Ayers CR; Powell-Wiley TM; Lakoski SG; Berry JD; Khera A; Das SR
    Hypertension; 2013 Jan; 61(1):105-11. PubMed ID: 23150502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.